Clinical Trial Update: Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer

View source ↗

Summary

The clinical trial evaluating plasma DNA as a surrogate for tumor biopsy to identify tumor genetic alterations in advanced breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Dartmouth-Hitchcock Medical Center | Conditions: Advanced Breast Cancer | Status: TERMINATED